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UTILITY OF AN EX VIVO HUMAN WHOLE BLOOD ASSAY FOR 
BACTERIAL KILLING ABILITY QUANTIFICATION 
YIBING WEI 
ABSTRACT 
 Infectious diseases caused by antibiotic resistant bacteria are difficult to treat 
using traditional antibiotics and have emerged as a global public health problem (Bartlett, 
Gilbert, & Spellberg, 2013).  An alternative strategy to bypass antibiotic resistance in 
bacteria is to enhance the host immune system (Hancock, & Sahl, 2006), especially 
innate immunity (Ajesh, & Sreejith, 2009), in order to combat bacterial infections.  To 
verify the augmentation of innate immunity under certain stimuli, a quantifiable 
measurement of bacterial killing ability is needed.  A new method of using heparinized 
human peripheral whole blood and mild heated blood samples from the same individuals 
as comparisons has been developed. This assay was used to quantify the bacterial killing 
ability of phagocytic cells by measuring the bacterial load after co-culturing with the 
Gram negative bacteria Pseudomonas aeruginosa.  The assay shows that peripheral 
whole blood of healthy humans is capable of being activated ex vivo upon bacterial 
challenge and suppressing the bacterial load, while blood gently heated at 48oC for one 
hour failed to do so.  The morphology of the phagocytic cells was examined 
microscopically.  Phagocytosis of bacteria in neutrophils is observed in intact blood, and 
no such changes were found in heated blood.  The level of inflammatory cytokine 
interleukin 8 (IL-8) was elevated in intact blood after bacteria inoculation, while in the 
heated blood the cytokine level stayed at baseline, indicating a persistence of leukocyte 
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viability in whole blood and damaged leukocyte activity in gently heated blood.  The data 
show that the human peripheral whole blood assay is suitable as a method for ex vivo 
bacterial killing quantification with the mildly heated blood sample from the same 
individual as a comparison.  When kept at 37oC ex vivo, human whole blood can be 
activated upon bacterial challenge, produce inflammatory cytokines, reduce bacterial 
load, and phagocytes in the whole blood can successfully maintain their cell viability and 
capacity to phagocytose bacteria. 
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INTRODUCTION 
 
 With the indiscriminate use of antibiotics over the past several decades, antibiotic 
resistant infections have emerged as global threats causing an increased number of deadly 
infectious diseases, including pneumonia, gonorrhea, tuberculosis and salmonellosis 
(2013), retrieved from https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.  
The production rate of newly developed antibiotics has decreased steadily over the past 
30 years (Bartlett, Gilbert, & Spellberg, 2013), while a rapidly growing number of 
antibiotic resistant strains has been reported (2017, September 20) retrieved from 
https://www.who.int/news-room/detail/20-09-2017-the-world-is-running-out-of-
antibiotics-who-report-confirms, so it is inevitable that an alternative strategy to fight 
against antibiotic resistant infections would be sought.  A safer and more effective 
approach to eradicate pathogens without utilizing antibiotics is to augment the innate 
immune response of the host (Finlay, & Hancock, 2004).  As the first line of defense of 
invading pathogens, innate immunity responds to insults in a rapid and non-specific 
manner (Modlin, Brightbill, & Godowski, 1999), making it a potent candidate for the 
enhancement of bacterial killing ability of the host (Finlay, & Hancock, 2004).  Studies 
have shown that some endogenous peptides like cationic antimicrobial peptide CEMA 
(Scott, et al., 2000) and cathelicidin-related antimicrobial peptides LL-37 (Scott, et al., 
2002) have the ability to stimulate innate immune related gene responses in human 
macrophages.  Molecules from pathogens such as CpG oligonucleotides (Sparwasser, et 
al., 1998; Langa, et al., 2012) and lipopolysaccharide (LPS) (Vulcano, et al., 2001; Zerif, 
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et al., 2017) can strongly active innate immune cells like dendritic cells (DC) and natural 
killer (NK) cells in animal models and help produce cytokines in human whole blood 
models (DeForge, et al., 1992).  Exogenous ligands of cell surface receptors of innate 
immune cell have been shown to have promising effects on regulating innate immunity to 
treat cancers (Purdy, & Campbell, 2009; Palucka, & Banchereau, 2012; Krutzik, et al., 
2003)  and infectious diseases (Seki, & Brenner, 2008; Ward, McKenna, & Kroft, 2007). 
However, unlike antibiotics, the development of innate immune enhancers 
(modulators) requires involvement of three essential components: drugs, microorganisms, 
and host immune cells.  The traditional and definitive approach to test drug efficacy 
commonly refers to clinical trials on human subjects, which require an exhaustive 
understanding of the drug and usually numerous studies using animal models due to the 
potential risk.  Results from animal models may not translate into human studies because 
of the discrepancies between human and laboratory animals (Seok, et al., 2013; 
MacDonald, et al., 2002).  As a primary carrier of circulating immune cells, peripheral 
whole blood is usually regarded as human tissue containing almost every subset of 
immune cells (Muzykantov, 2002) and excellently reflects the biological condition of the 
host.  Blood is also a medium in which immune cells and drugs (Wohlfart, Gelperina, & 
Kreuter, 2012; Hickey, & Kubes, 2009) can be delivered, as this allows them to be taken 
to the sites of infection.  It is also viable because pathogens disseminate from organ to 
organ via the blood system (Walker, et al., 2000) .  Therefore, by using peripheral blood, 
this whole blood assay could be an easy, fast, and close-to ideal method to test out how 
drugs function in enhancing immune cell’s microbiocidal abilities while retaining a 
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natural environment, as well as a dynamic cell-cell/cell-protein/protein-protein 
interactions (Damsgaard, et al., 2009) , especially compared to isolated immune cell 
activation methods (Silva, D., et al., 2013; Chen, J., et al., 2010; Norman, T.E., et al., 
2005).  
This thesis describes a method in a laboratory setting using freshly drawn 
peripheral venous whole blood from healthy adult volunteers and challenged it with 
bacteria ex vivo.  The goal was to find a new and innovative bacterial killing ability 
measurement of innate immune cells.  To do this, mild heated blood sample from the 
same individuals were used as a control, aiming to only eliminate viability of the white 
blood cells, while still maintaining most of the cell-protein interactions, thus making 
testing of an innate immune enhancer directly related to cellular activity.  Distinctive 
from the existing whole blood assay (Chen, J., et al., 2010) , this method offers the 
comparison with mild heat inactivated blood to precisely address whether the bactericidal 
effect is due to the innate immune cell activities or drug/blood molecule cross-
interactions with the bacteria, providing a useful tool for drug efficacy analysis. 
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METHODS 
 
Subjects 
Subjects enrolled were healthy adults who met the inclusion criteria of 
considering themselves to be in good health on the day of donation.  Subjects who took 
daily medication to treat a chronic disease were specifically excluded from the study.  All 
participants were informed about the aims and potential risk of being a part of the study 
and a written consent form (Appendix 1) was obtained from each volunteer in accordance 
with the ethical requirements of the Boston University Institutional Review Board (IRB) 
(Appendix 2).   
Blood Collection 
A total volume of 18 mL of venous peripheral blood was collected sterilely from 
the arm with a 21-gauge butterfly needle with a syringe attached.  The needle and syringe 
were anticoagulated with 200 units of heparin sodium (McKesson Packing Service, UNII: 
ZZ45AB24CA) to prevent coagulation.  At the end of blood draw, after removal of the 
butterfly needle, the syringe was inverted a few times to ensure that the blood was well 
mixed.  
Blood heating method 
After the blood draw, 0.5 mL of blood was aliquoted sterilely into 1.5 mL 
microcentrifuge tube to quantify red blood cell and hemoglobin counts (HemaVET 
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HV950 multispecies hematology instruments, Drew Scientific, Inc.).  The rest of the 
blood was divided sterilely into two closed cap tubes with equal volumes and kept at 48 
oC (dry bath incubator, Fisher Scientific) or at 37 oC (HELA cell 500, Thermo Electron) 
for one hour.  After heating, red blood cell counts and hemoglobin concentration were 
measured from both the heated and intact groups. 
Human whole blood bacterial killing assay 
McFarland standard  
Pseudomonas aeruginosa (Boston 41501; ATCC, Manassas, VA) was streaked on 
TSA agar plates with sheep blood (Remel, Lenexa, KS) using sterile techniques and 
incubated overnight at 37 oC.  Bacterial colonies were picked from the plate and 
resuspended in LB broth (Lennox, Fisher Scientific, Fair Lawn, NJ) to reach a uniform 
absorbance of 0.270 (OD600).  Absorbance was measured using a UV/Vis 
spectrophotometer (Beckman DU530, Beckman Coulter Inc., Brea, California).  The 
bacteria were centrifuged at 2,000g for 7 minutes (Eppendorf centrifuge 5415R), and the 
cell pellet was washed in 7 mL of Hank's balanced salt solution (HBSS, Cellgro 
Corning).  The bacteria were centrifuged again using the same method and resuspended 
in HBSS to reach the final concentrations as required. 
Bacteria incubation 
Bacteria were added to LB broth/intact blood/heated blood to reach the final 
concentrations as required in 1.5 mL tubes with a closed cap.  Cultures were placed in an 
incubator (HERA cell 150, Thermo) at 37oC with orbital shaking at 80 rpm. 
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Bacterial burden 
Tubes with bacteria were taken out after 0 hours, 4 hours, and 24 hours of 
incubation to determine the bacterial growth.  To ensure uniform concentrations, tubes 
were gently vortexed before each dilution.  30 μL of bacterial culture was pipetted into 
270 μL deionized water and mixed thoroughly to reach homogeneity.  Serial 10-fold 
dilutions were performed on a 96-well plate using a multi-channel pipettor to minimize 
sample to sample variation.  Dilutions of the bacterial concentration that were optimal for 
manual plate counting were steaked on TSA agar plates with sheep blood, then incubated 
overnight at 37oC.  Plates with colony forming units (CFUs) of 30 to 300 were counted 
for determination of final bacterial burden based on dilution factors. 
Blood smear and staining 
A blood smear was performed for each time point of incubation for the 
observation of blood cell morphology.  Total volume of 10μL of well-mixed blood 
sample was pipetted at one end of pre-cleaned glass micro slides (Rite-On, Clay Adams, 
Parsippany, NJ) to form a clear-edged dot, another glass slide was used to evenly 
distribute blood sample by pressing the blood dot and dragging over to the other end of 
the slide.  A feather edge was formed at the place where the blood sample layer thinned 
and a rainbow effect was observed at the feather edge to confirm a successful blood 
smear. 
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Diff-Quik staining 
Diff-Quik is a simplified hematology Wright-Giemsa staining which generates 
results in less than 10 minutes.  Blood smear slides were air-dried and dipped in Diff-
Quik staining solutions series (Camco Stain Pak, Cambridge Diagnostic Products Inc., 
Fort Lauderdale, FL) according to the manufacturer’s instructions.  Stained slides were 
air dried and preserved for subsequent microscopic examination. 
Hematology imaging  
Diff-Quik stained hematology images were taken with Olympus BX51 
microscope (Model BX51TF, Tokyo, Japan) and captured using Celestron Digital 
Microscope Imager (Torrance, CA) Digital Microscope Suite 2.0 software at 40x and 
100x magnifications. 
ELISA 
 Human plasma IL- 8 levels were evaluated using a sandwich enzyme-linked 
immunosorbent assay (sandwich ELISA).  After incubation, the blood samples were 
centrifuged at 1,500g at 23oC for 5 minutes.  Plasma was collected and stored at -20oC 
prior to the assay.  On day 1, IL-8 primary capture antibody (anti-hCXCL8/IL-8 purified 
mouse monoclonal IgG, R&D System) was diluted in 1x PBS at room temperature with a 
dilution factor of 1:1000 for plate coating.  50μL of capture antibody was added to each 
well on a 96-well plate (NUNC Maxisorp plate P/N 439454, Thermo Fisher Scientific) 
and was stored at 4oC overnight.  The plate top was covered with a plate sealer to avoid 
evaporation and contamination.  On day 2, the pre-coated plate was taken out of the 
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refrigerator and extra liquid was gently washed off using ELISA wash buffer (diluted 
from 20x ELISA wash buffer in H2O from Millipore system, 20x ELISA wash buffer was 
made with 10mL Tween 20, 800mL 25x PBS and 192mL H2O from Millipore System) 
with a microplate washer (BioTek ELx405).  150μL of Blocking Buffer (Blocker 
BLOTTO in TBS 37530, Thermo Scientific) was then added to each well and the plate 
was shaken with an orbital shaker (MTS 2/4 digital microtiter shaker, IKA) for 1 hour to 
block non-specific binding and reduce background interference.  After blocking, the plate 
was washed with wash buffer.  The standard was thawed and diluted in Dilution Buffer 
(5mL Blocking Buffer, 2.5mL 2% BSA in PBS, 25μL Tween 20, 42.5mL 1xPBS) to 
generate a 2-fold dilution series.  Plasma samples were diluted in Dilution Buffer.  50μL 
of the standard or diluted plasma were added to each well and placed on an orbital shaker 
for 2 hours.  After 2 hours the plate was washed with wash buffer and 50 μL of secondary 
biotinylated Detection Antibody (biotinylated anti-hCXCL8/IL-8 affinity purified goat 
IgG, R&D System) was added and the plate was shaken for 2 hours.  The plate was 
washed again and 50μL pre-warmed (37oC) Horseradish Peroxidase (HRP, 1:20,000 
diluted in Dilution Buffer) was pipetted in each well and the plate was shaken for 30 
minutes.  The plate was washed and 100μL 3,3’,5,5’- Tetramethyl-Benzidine (TMB, T-
2885, Sigma-Aldrich) substrate solution (TMB solution was prepared with all elements 
added in order: 12.5mL sodium acetate, 2μL H2O2 and 125μL TMB 1% stock, TMB 1% 
stock was made with 1g TMB and 100mL DMSO) was pipetted into each well and the 
plate was incubated in the dark for color development for 20~30 minutes. When pigment 
started to reveal in the lowest concentration of the standard series, the plate was taken out 
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of the dark and 100μL of H2SO4 (107mL reagent grade sulfuric acid in 893mL purified 
water) was added to each well to stop the reaction and the final optical density (O.D. at 
456/670 nm) of standard series and sample dilutions were quantified with a plate reader 
(TECAN SpectraFluor Plus). 
Drugs and compounds 
Antibiotics 
Ampicillin sodium salt (Fisher Scientific, CAS 69-52-53, Fair Lawn, NJ) was 
used as an antibiotic to be added in LB/intact blood/heated blood to control the bacterial 
growth.  Ampicillin sodium salt powder was stored in 4oC and dissolved in HBSS at 
0.16g/mL (1.6mg/10μL) and 0.005g/mL (0.05mg/10μL) as working solutions.  10μL 
ampicillin working solution was delivered to 500μL system of bacterial culture before 
incubation to achieve the final concentrations of 3.3mg/mL or 0.1mg/mL. 
Statistical analysis 
Statistical analysis was performed with Prism software version 7.0 (GraphPad, La 
Jolla, CA).  Hematologic data of total RBC and hemoglobin, and IL-8 concentrations in 
plasma were analyzed using the two-tailed paired t-test.  Comparisons of CFUs between 
intact blood and heated blood at each time point were analyzed using the one-tailed 
paired t-test and one-way ANOVA if more than two groups were involved. 
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RESULTS 
Mild heating inactivation does not cause hemolysis  
Extended heat stress can produce fragmentation and rupture of the cell membrane 
of erythrocytes and cause hemolysis in peripheral blood as may be observed in burn cases 
of animals (Loebl, Baxter, & Curreri, 1973) and humans (Paradkar, et al., 2008).  It is 
well recognized that growth of bacteria, including P. aeruginosa, relies on iron (Ganz,  
Nemeth, 2015; Jenne, S. Liao, & B. Singh, 2018) and the extracellular concentration of 
free iron in plasma is lower than the level for bacteria to thrive (Jenne, S. Liao, & B. 
Singh, 2018) .  However, hemolysis caused by heat and leakage of iron-containing 
hemoglobin from inside of erythrocytes to plasma could possibly increase the plasma iron 
concentration and lead to the overgrowth of P. aeruginosa.  Therefore, we examined the 
total RBC (Fig. 1A) and net hemoglobin (HB, including intracellular and extracellular) 
(Fig. 1B) level of blood samples (n=4) at the time of blood draw, at the beginning of 
incubation (0 hour) after 4-6 hours and 21-24 hours of incubation respectively to 
determine if there was rupture of erythrocytes.  Visually, after heating, plasma from the 
heated blood group has a subtle tint of pink color but as indicated by HemaVET counting, 
total RBC and HB number of heated blood at 0 hours (at the end of one-hour heating and 
at the beginning of bacteria inoculation), 4-6 hours and 21-24 hours is not lower than 
intact blood (kept at 37oC simultaneously when heating method was conducted) (Fig. 1A, 
1B).  Instead, counterintuitively, at later time points, a trend of RBC count being slightly 
higher in heated blood was observed.  This is probably caused by the accumulated 
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evaporation after prolonged incubation.  Overall our data indicates no significant 
hemolysis is caused by heating at a mild temperature of 48oC for one hour. 
 
 
 
 
 
 
 
 
 
 
Figure 1.  RBC count and HB concentration.  Human whole blood samples were analyzed at the 
time of drawing (initial), beginning of the incubation (0 hours), after 4-6 hours and after 12-24 hours of 
incubation.  (A) The counts of red blood cells (B) and total hemoglobin concentration were not statistically 
different between intact blood and heated blood.  Data was obtained using HemaVet 950FS Auto Blood 
Analyzer (Drew Scientific), n=4 for heated blood and n=4 for intact blood.  Data is demonstrated as 
mean±SEM.  No data were statistically different at p£0.05.  (n.s. = non-significant) 
Bacteria are engulfed into phagocytic cells in intact blood while heat 
inactivated blood fails to ingest bacteria 
Upon pathogen challenge, phagocytic cells such as neutrophils (Sagoo, et al., 
2016) and monocytes/macrophages (Hirschfeld, et al., 2017) in peripheral blood stream 
A	
B	
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are the first responders.  There are usually three major consecutive steps involved in the 
acute innate immune reaction of phagocytic cells in the eradication of pathogens: 
phagocytosis, killing and digestion of bacteria and fungi.  From the formation of the 
phagosome to fusion of the phagosome with the lysosome, bacteria and fungi are 
eradicated by several mechanisms of phagocytes including reactive oxygen spices (ROS) 
(Brinkmann, & Zychlinsky, 2007) within the lysozymes produced by phagocytic cells.  
Some phagocytic cells also clear pathogens through projecting chromatin and forming 
extracellular nuclear traps (NETs) (Gottlieb, et al., 2018) .  Both phagosome/lysosome 
and NETs (van de Veerdonk, et al., 2011) are microscopic cellular structures and can be 
visualized under a light microscope.   
As shown in the microscopic images, phagocytic cells (neutrophils) in blood kept 
at 37oC have a well-defined outline and intact cell membranes (Fig. 2A).  The typical 
multiple-lobe nuclear structure for neutrophil is clearly demonstrated in the blood smear 
slide taken before the addition of bacteria culture.  After a 4-hour incubation with 
bacteria, numerous rod-like bacteria particles could be seen inside the cytoplasm of the 
neutrophil and vesicles started to assemble in cells from intact blood which indicates the 
formation of neutrophil phagosomes or potentially phagolysosomes (Fig. 2B).  In the 
extracellular space, several strings of thin fibrils occur next to neutrophil wrapping 
around clusters of bacteria which could possibly be the neutrophil extracellular nuclear 
traps (NETs) produced by dying neutrophils for the purpose of slowing down the 
dissemination of bacteria (Fig. 2B).  The evidence suggests that for whole blood kept at 
the physiological temperature, phagocytic cells are active and have a regular and rapid 
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response to the ex vivo bacterial challenge.  Conversely, neutrophils cells in whole blood, 
after one-hour mild heating at 48oC lost their signature multiple-lobe nuclear structure 
and displayed a botryoid “grape-like” pattern (Fig. 2C, 2D).  In addition, the morphology 
changes from 0 to 4 hours in neutrophils in heated blood are very minor.  Bacteria are 
neither colocalized with the phagocytic cell nor engulfed into the neutrophils in heated 
blood, suggesting an impaired white blood cell function.  We have no direct evidence of 
the existence of cell membrane of neutrophils in heated blood at 0 hours or 4 hours, 
however, the dark-purple stained cell-like structure indicates the integrity of the cell and 
further confirms that heating at 48oC for one hour is not a crucial condition for cell to be 
completely destroyed.  A majority of red blood cells still maintained their biconcave disc 
structure in heated blood with only a few losing their shape, which is consistent with the 
RBC count being unaffected in heated blood and only a subtle hemolysis happens 
resulting in the little pink color in the plasma (Fig. 2C, 2D).  Hematology imagining 
evidence suggests normal phagocytic cell activity in heparinized syringe-drawn human 
whole blood sample and a depleted white blood cell function in the heated inactive 
control. 
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Figure 2.  Phagocyte morphology on blood smear slides.  Microscopy pictures were captured 
using Celetron Digital Microscope Imager Suite 2.0 at 100x magnification.  All blood smear slides were 
treated with Diff-Quik staining.  (A) Neutrophil at 0 hours of incubation in intact blood.  The 
multilobulated nuclei structure is well preserved (blue arrow).  (B) Neutrophil after 4 hours co-incubation 
with P. aeruginosa.  Bacteria were engulfed into the neutrophil and phagosomes were assembled (yellow 
arrow).  Fibril like structure was generated in the exocellular space (red arrow).  (C & D) Neutrophil at 0 
hours and 4 hours of co-incubation with in P. aeruginosa in heated blood, displaying a botryoid “grape 
like” pattern (green arrows).  Morphological changes in the neutrophils between 0 hours and 4 hours were 
minor.   
A	
C	
B
	
D
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Leukocytes are active in intact blood and produce IL-8 after bacterial 
challenge  
Another benchmark trait of active leukocytes is the production of inflammatory 
cytokines such as IL-1β (Gregory, et al., 1998) , tumor necrosis factor (TNF) α (Gregory, 
et al., 1998) , IL-6 and IL-8 (Rot, 1992) etc.  Being one of most studied cytokines, 
neutrophil chemoattractant IL-8 plays a significant role in the inflammatory response to 
bacterial infections, including migration (Kukulski, et al., 2009; Elsner, et al., 1992) and 
excitation (Djeu, et al., 1990) of several leukocytes, degranulation (Elsner, et al., 1992) 
and lysosomal enzyme release (Phillipson, & Kubes, 2011) of neutrophils, as well as the 
expression of adhesive molecules of granulocytes (Reimer, 1981) .  An elevated plasma 
IL-8 level indicates an immunologically functional cellular signaling transduction, gene 
transcription and protein translation-transportation system of cells upon bacterial 
challenge. 
ELISA data showed plasma IL-8 levels increased over time in intact blood 
samples (n=4) at 4 hours and 24 hours (Fig. 3) after two different doses of bacterial 
challenge (5x107 CFU/mL and 5x108 CFU/mL).  This indicates leukocyte viability in 
blood kept at 37oC.  On the other hand, IL-8 plasma level in mild heat inactive whole 
blood (n=4) remained at baseline (Fig. 3) both at 4 hours and 24 hours after bacterial 
inoculation, indicating a defect in leukocyte activity.  
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Figure 3.  Production of inflammatory cytokine IL-8 upon bacterial challenge.  Initial plasma was 
the sample obtained from the whole blood at draw which was centrifuged, aliquoted and kept at room 
temperature immediately after collection, without heating or bacterial challenge; intact blood plasma was 
the sample from whole blood after kept at 37oC for one hour; heated blood plasma was the plasma sample 
from whole blood kept at 48oC for one hour; time initial was one hour after the heating method was 
completed; 0 hour was the beginning of incubation with bacteria inoculated into the blood; 4 hours and 24 
hours was the time span of the incubation.  (A) ELISA results of plasma IL-8 levels at a lower dose of 
bacterial challenge (5x107 CFU/mL), plasma IL-8 in heated blood remained at baseline at 0 hours, 4 hours 
and 24 hours, except one individual detaching form the main data body; starting from 4 hours, intact blood 
had a scientifically elevated IL-8 level.  (B) ELISA results of plasma IL-8 levels at a higher dose of 
B	
	
A	
B	
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bacterial challenge (5x108 CFU/mL), similar to the lower dose, plasma IL-8 remained at baseline in all time 
points in heated blood while in intact blood IL-8 had a significant increase at 4 hours.  Data are shown as 
mean±sd to illustrate the individual difference, two-tailed paired t-test is used for statistical analysis.  Data 
is statistically significant at p£0.05. 
Whole blood bacterial killing assay determines 5x107 CFU/mL and 24 hours 
to be the most optimal incubation dose and time  
Phagocytic cell function persists in intact heparinized peripheral human whole 
blood when challenged with bacteria ex vivo and heat inactive whole blood loses 
phagocytic cell’s viability.  In order to quantify bactericidal ability of human whole 
blood, the CFUs of both intact blood and heated blood at different time points were 
measured.  The two aims of this experiment were to 1) define a bacteria inoculum that is 
high enough to generate a statistically different CFUs in intact blood culture and heated 
blood culture, and to 2) determine an incubation time point between the end of the log 
phase of growth curve where bacterial proliferation continues and the beginning of 
stationary phase on the growth curve when phagocytic cells have enough time to take 
effect as the majority of the bacteria are still alive. 
For the six P. aeruginosa inoculation concentrations we tested (5x103, 5x104, 
5x105, 5x106, 5x107, 5x108 CFU/mL), CFUs of intact blood at 5x103 and 5x104 CFU/mL 
are held before log growing phase, having a bacterial load lower than (or the same as) 
earlier time points at 24 hours (Fig. 4A, 4B) indicating a failure of reaching the log phase 
of growth.  This suggests an insufficient challenge at 5x103 and 5x104 CFU/mL.  CFUs of 
heated blood at 5x108 CFU/mL achieved growth plateau after 4 hours and began to 
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decline at an early time point of 6 hours (Fig. 4F) suggesting the bacterial challenge to be 
overwhelming.  On the other hand, 5x105, 5x106, 5x107 CFU/mL have drastic increases 
of bacterial growth both in intact blood and heated blood after 21 hours of incubation 
extending to 24 hours (Fig. 4C, 4D, 4E).  Compared to heated blood, CFUs of intact 
blood is significantly lower at 5x105, 5x106, 5x107 CFU/mL at all times, with both intact 
and heated blood being lower than LB broth.  This evidence suggests that an initial 
inoculum ranging from 5x105 to 5x107 CFU/mL and incubation time from 21 to 24 hours 
to be the most optimal conditions for the human whole blood bacterial killing ability 
quantification assay.  In order to maximize the bacterial challenge, we choose 5x107 
CFU/mL and 24 hours for further experiments.  
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Figure 4.  Bacterial growth curves.  CFUs of P. aeruginosa at 0 hours, 4 hours and 24 hours co-
incubating with LB broth, intact blood and heated blood inoculated with concentrations of (A) 5x103 
CFU/mL, (B) 5x104 CFU/mL, (C) 5x105 CFU/mL, (D) 5x106 CFU/mL, (E) 5x107 CFU/mL, and (F) 5x108 
CFU/mL of bacteria.  After 24 hours, with of 5x103 CFU/mL, intact blood had 5-log reduction of bacterial 
load compared to LB and heated blood (p=0.02).  CFUs between LB, intact blood and heated blood started 
to deviate at 4 hours and continued to 24 hours.  Intact blood reduced bacteria load at 24 hours by 2 logs 
with 5x104 CFU/mL (p=0.03), 1 log with 5x105 CFU/mL (p=0.002), 5x106 CFU/mL (p=0.0004) and 5x107 
CFU/mL (p=0.009) when compared to heated blood.  At 6 hours, intact blood reduced bacterial load by 1 
log with 5x108 CFU/mL (p=0.0001).  From 5x103 CFU/mL to 5x107 CFU/mL, bacteria load in LB broth at 
the end of incubation was the highest among all.  n=3 for 5x103 CFU/mL and 5x104 CFU/mL, n=7 for 
5x105 CFU/mL and 5x106 CFU/mL and n=13 for 5x107 CFU/mL and 5x108 CFU/mL in all three groups 
(LB, heated and intact blood).  Data were shown as mean±SEM and statistically analyzed with one-way 
ANOVA at each time point between LB, intact blood and heated blood.  (p<0.05 *, p<0.01 **, p<0.001 
***, p<0.0001 ****). 
Intact blood has a significantly higher bacterial killing ability than heated 
blood 
Based on the growth curves, we established a standard protocol for the whole 
blood bacterial killing assay using 5x107 CFU/mL as the initial bacterial concentration in 
blood culture and 24 hours as incubation end time.  The CFUs of individual cases at 4 
hours and 24 hours were studied (n=5).  Overall, at 4 hours and 21 to 24 hours, with 
5x107 CFU/mL, intact blood successfully kept the CFUs one-log lower than heated 
blood, showing an impaired bacterial killing with the heating method (Fig. 5A, 5B).  The 
ratio of CFUs of heated blood to intact blood differs among volunteers indicating a 
		 21	
discrepancy of the immune background of each individual, even though each donor was 
considered healthy.  At 4 hours with a higher dose of 5x108 CFU/mL, there is a trend of 
higher CFUs in heated blood compared to intact blood overall, however, 2 of 8 cases 
showed a reduction of CFUs in heated blood which could be an effect of bacterial natural 
death at the decline phase of growth curve, further confirming an overwhelming 
challenge at 5x108 CFU/mL (Fig. 5C). 
 
BA	
C	
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Figure 5.  Time-point CFUs of individual cases.  (A) Bacteria load at 4 hours with 5x107 CFU/mL 
indicated a trend of higher CFUs in heated blood (n=8 for each group, p=0.06).  (B) Bacteria load at 21-24 
hours of incubation with 5x107 CFU/mL showed a significant reduction of CFUs in intact blood (n=5 for 
each group, p=0.04).  (C) Bacteria load of intact blood at 4 hours with 5x108 CFU/mL was significantly 
lower than heated blood (n=8 for each group, p=0.01).  Data from the same individual were connected.  
One-tailed paired t-test was used for statistical analysis under the premise of CFUs in heated blood being 
higher than intact blood.  Data is statistically significant at p£0.05. 
Antibiotics controls bacteria growth only at a higher dose in human whole 
blood 
As human tissue, whole blood contains multiple components which interact 
dynamically.  Antibiotics have been used as a traditional strategy for the control of 
bacterial growth over decades.  Here we demonstrate a scenario where the literature 
recommended minimal inhibition concentration (MIC) of ampicillin generated from a 
non-biological system-LB broth for P. aeruginosa (Fass, & Barnishan, 1979) fails to 
prevent bacteria growth in intact whole blood.  
Several studies have shown that the β-lactam antibiotic ampicillin suppresses P. 
aeruginosa growth at a minimal concentration of 0.1mg/mL in LB media (Hoogkamp-
Korstanje, & Westerdaal, 1979; Brideau, et al., 1996) .  We found with 5x107 CFU/mL in 
intact blood with 0.1mg/mL ampicillin, surprisingly, CFUs are significantly higher than 
intact blood with only a vehicle (n=3) at 24 hours, while in heated blood, 0.1mg/mL of 
ampicillin successfully prevents bacterial growth (Fig. 6A).   
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In patients, a recommended dose for intravenous or intramuscular injection of 
ampicillin is 50 to 250 mg/kg/day (Feb. 2008) retrieved from 
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d0a2f64e-e474-4dd0-
be29-35fce160db72&type=display, with a blood to body weight ratio of 75mL/kg.  We 
convert the working concentration of ampicillin to be 0.67 to 3.33mg/mL in whole blood, 
which is 6 to 30 times of the MIC in LB media.  A second set of bacteria growth 
experiment was conducted with 3.3mg/mL ampicillin, the average CFUs in ampicillin 
added intact blood was lower than the ampicillin free group (Fig. 6C).  All these data 
indicate that whole blood is a complicated system.  For the delivery of antimicrobial 
drugs, data produced from non-biological systems is not completely transferable to the 
whole blood assay.  Whole blood is a better reflection of the host and can bridge the gap 
of in vivo and in vitro studies in terms of drug efficacy (Bledsoe, & Grizzle, 2013) . 
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Figure 6.  CFUs with antibiotics.  (A) Bacteria load at 0 hours, 4 hours and 24 hours of incubation 
with 5x107 CFU/mL of bacterial and a lower dosage of 0.1mg/mL ampicillin.  At 24 hours, CFUs is higher 
in heated blood group compared to intact blood (n=3, p=0.09); CFUs were significantly higher in intact 
blood with ampicillin than intact blood without ampicillin (n=3, p=0.005); CFUs had a trend to be lower in 
heated blood with ampicillin added than heated blood without ampicillin (n=3, p=0.2).  B: bacteria load at 
0h and 4 hours of incubation with 5x108 CFU/mL and a lower dosage of 0.1mg/mL ampicillin.  At 4 hours, 
no significant differences were observed between intact blood-heated blood, intact blood with ampicillin-
intact blood without ampicillin or heated blood with ampicillin-heated blood without ampicillin.  (C) 
Bacteria load at 0 hours, 4 hours and 24 hours with 5x107 CFU/mL of bacteria and a higher dosage of 
ampicillin of 3.3mg/mL.  Only 2 individuals were tested, the average of CFUs was lower at 24 hours for 
intact blood when compared to heated blood; the average of CFUs was also lower at 24 hours in intact 
blood (heated blood) with ampicillin group when compared to intact blood (heated blood) without 
ampicillin.  Data were displayed as mean±sd, and paired t-test was used for statistical analysis in (A) and 
(B).  Data is statistically significant at p£0.05.  
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DISCUSSION 
 
 Antibiotic resistant bacterial infections have become a global health crisis due to 
the overuse and misuse of antimicrobial drugs over the years.  An alternative solution to 
antibiotic resistance is through the enhancement of the host innate immunity and 
harnessing the natural bactericidal function of the innate immune cells such as 
macrophages and neutrophils to kill bacteria.  In order to evaluate the efficacy of 
different immunity modulators, a quantifiable measurement of phagocyte bacterial killing 
ability is needed.  In this study, one of the easiest accessed human biospecimens, 
peripheral whole blood (Mollnes, et al., 2002) , was utilized as a medium for pathogen 
culture ex vivo.  This mimics the real scenario of immune reactions in the host when 
encountering an infection (Bledsoe, & Grizzle, 2013, McAdams, Srinivasan, & Arkin, 
2004) , aiming to find a platform in a laboratory setting for a simple and fast 
quantification of the bacterial killing ability, which closely reflects each individual. 
Bacteria adapt to environmental stress quickly through rapid mutations (Lewis, 
2013) .  Whatever mechanisms of bacteria growth or proliferation antibiotics directly 
target, there are strains of bacteria that are resistant to it and are able to expand in the 
presence of the drugs (Pruenster, et al., 2009) .  A promising alternative strategy is to 
avoid the direct reaction between drugs and microbials and find modulators for host 
immunity that act directly on human immune cells.  Our study offered a carefully 
designed control group of gently heated whole blood from the same individual to not just 
eliminate cell variability, but also to maintain the activity of most immune active 
components (such as complement and immunoglobins).  The gently heated blood could 
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be used as a comparison to intact blood, kept at 37oC, for the evaluation of bacterial 
killing.  Our data confirmed blood heated at 48oC for one hour is unable to produce the 
inflammatory cytokine IL-8 when challenged with P. aeruginosa.  The blood is not 
capable of phagocytosis and controlling the growth of bacteria, even though no 
significant hemolysis was observed throughout the 24-hour incubation.  On the other 
hand, CFUs data, phagocyte morphology images, and IL-8 ELISA data all indicated an 
active immuno-function persisting in the intact blood group. 
The serial bacterial dose growth curves provided insight on the most optimal 
incubation conditions for P. aeruginosa.  Our data showed that an initial inoculating 
concentration ranging from 5x105 to 5x107 CFU/mL and an incubation time from 21 to 
24 hours are the most feasible conditions for human whole blood assay with P. 
aeruginosa.  Significantly different CFU counts for heated blood and intact blood, as 
bacterial killing ability in intact blood was proven with additional growth of bacteria 
detected at the end of incubation.  
A few intriguing observations were made throughout the study.  It is worth 
mentioning that the plasma IL-8 level the in heated blood sample from one individual 
was above baseline at 24 hours with an initial bacterial concentration of 5x 107 CFU/mL 
(Fig. 3A).  Other than a potentially unsuccessful heating process, it is possible that, due to 
the binding ability of IL-8 to Duffy antigen on red blood cells (Darbonne, et al., 1991), 
lysed erythrocytes of this individual acted as reservoirs (Coster, et al., 2007) which 
released pre-formed IL-8 into plasma after heat disruption and prolonged incubation, 
resulting in an elevated plasma IL-8 level when there is no leukocyte activity.  
		 28	
Individual volunteers had different antibacterial responses (Bauer, et al., 2013).  
CFUs after 4 or 24 hours of intact blood and heated blood showed a range of bacterial 
killing ability among 5 donors, with different CFU ratios of heated blood to intact blood, 
indicating a distinctive immune background of in the human population.  The CFUs data 
with the β-lactam antibiotic ampicillin further confirmed the complex milieu of the 
human whole blood and that a single dose of ampicillin higher than MIC could prevent 
bacterial growth in intact blood.  These findings emphasized the importance of the whole 
blood assay as being a more precise approach than a non-biological system.  
Finally, among five initial concentrations of P. aeruginosa we tested (5x108 
CFU/mL not included), we were able to extend the incubation time to 24 hours.  Out of 
20 individuals, the highest CFU counts in either LB or heated blood were at a small range 
of 108 to 109, indicating there is a maximum bacterial growth capacity of 0.5 mL 
incubation volume in 24 hours.  Taken together, the ideal assay conditions for human 
whole blood is with an initial bacterial inoculum of 5x105 CFU/mL to 5x107 CFU/mL 
and incubation time of 21 hours to 24 hours. 
The limitations of our studies include that this is a single-site study and only a 
small number of volunteers (n=20) were consented, while a country wide study could 
provide a better representation of the population.  Additionally, as a self-reported health 
assessment was adopted as the major inclusion criteria and there was no access to the 
volunteers’ age and ethnicity, as well as medical history and vaccination status.  All the 
participants were not completely ensured to be healthy.  Another factor that should be 
taken into consideration is that the collection time of all 20 volunteers overlapped with 
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the epidemic flu season in Boston (2018-2019) retrieved from 
https://www.cdc.gov/flu/about/season/flu-season-2018-2019.htm.  Therefore, the data 
could be slightly skewed as some of the participants might have inflammatory symptoms.   
 Overall, data in this study showed ex vivo utility of human peripheral whole blood 
is an applicable method for the evaluation of killing ability of bacteria, with the 
comparison to the gently heated blood sample from the same individual, which was 
proven to not cause hemolysis.  A practical bacterial concentration and incubation time 
for the most optimal measurement is 5x107 CFU/mL and 24 hours, respectively.  The 
data showed a persistent leukocyte viability in the intact blood sample and an impaired 
one in the heated blood group, as confirmed by cell morphology and cytokine secretion.  
Individual cases study indicated a diverse immune background among different donors.  
Application of antibiotics in human whole blood assay a distinctive characteristic of 
blood as compared with LB broth to be more complicated.   
Additional studies are also needed to explore potential leukocyte/phagocyte 
enhancing molecules using human whole blood assay as described, and to further address 
the mechanisms of specific modulators in the enhancement of bacterial killing process as 
seeking for an alternative strategy to defeat antibiotic resistant infections   
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APPENDIX 
Appendix 1. RESEARCH CONSENT FORM 
 
Basic Information 
 
Title of Project: The Mechanism(s) of NK1R Agonists Enhancing Pathogen 
Clearance of Phagocytes in Human Whole Blood 
 
IRB Number: H-37247 
 
Principal Investigator: Daniel G. Remick 
remickd@bu.edu 
670 Albany St 4th Floor, Suite 407, 
Boston, MA 02118 Study Phone 
Number: 617-414-7914 or 617-414-7043 
 
Overview 
We are asking you to be in a research study. A research study is an organized way of 
collecting information about scientific questions. This form will tell you what you should 
expect if you agree to be in the study. There are programs in place to make sure that 
investigators fulfill their obligations listed in this form. 
 
It is your decision whether or not to join the study. We are doing the research to find 
out an alternative strategy to combat infections. If you agree, you will provide no more 
than 18ml blood. Donating this amount of blood usually only takes 15 minutes which is 
the total amount of time you will be in the study. You will find more information about 
what will happen in this study later in this form. 
 
The main risks of being in the study are bruising from having your blood drawn. 
You will find more information about risks later in this form. 
 
Purpose 
You are being asked to have a phlebotomist take some blood from your vein. This blood will be 
put in a tube to see if the cells in the blood can be stimulated to kill bacteria. 
 
What Will Happen in This Research Study 
Your blood will be collected by research staff in Department of Pathology and Laboratory 
Medicine, at Boston University School of Medicine. Your blood will be used by the scientists 
in this study. If you agree to participate, you will allow us to do the following: 
• Collect around 18 ml blood 
• The samples will only be used to study immune cell functions 
 
The research lab will store your blood samples in a secured space in 4th flood 670 Albany street, 
only approved researchers can have access to your samples. You will not be identified 
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personally by participating this study. 
 
The ways we will protect your privacy and confidentiality are described in a separate section 
later in this form.  
 
Risks and Discomforts 
The risk of participating in this study is minimal. The major risks from drawing blood 
includes pain, bruising, or infection at where the blood is drawn. These are the same risks 
you face any time you have blood drawn in a doctor’s office. 
Potential Benefits 
You will receive no direct benefit from your participation in this study. However, your 
participation may help the investigators better understand how human immune system works. 
It is unlikely that this information will directly benefit you. You should not donate to try to 
learn information about your own health. You will not be notified about any personal 
research results. 
 
Costs and Payment 
You will be given a $15 gift card if you agree to donate. You will still be paid even the blood 
draw is not successful. There is no payment to you or your family if commercial products or 
treatments have been developed from the use of your samples or information. There are no 
costs to you for participating in this research study. Similarly, there will be no cost to you for 
the use of your samples or for storing your blood. 
 
Confidentiality 
We will store your information in ways we think are secure. We will store biological 
samples taken from your body (such as urine, blood, or tissue) as coded samples in a 
freezer. We will store paper files in locked filing cabinets. We will store electronic 
files in computer systems with password protection and encryption. However, we 
cannot guarantee complete confidentiality. 
 
We will share research data where we have removed anything that we think would 
show your identity. There still may be a small chance that someone could figure out 
that the information is about you. Such sharing includes: 
• Publishing results in a medical book or journal. 
• Adding results to a Federal government database. 
• Using research data in future studies, done by us or by other scientists. 
• Using biological samples in future studies, done by us or by other scientists. 
 
Subject’s Rights 
By consenting to be in this study you do not waive any of your legal rights. Consenting means 
that you have been given information about this study and that you agree to participate in the 
study. You will be given a copy of this form to keep. 
 
If you do not agree to be in this study or if at any time you withdraw from this study you will not 
suffer any penalty or lose any benefits to which you are entitled. Your participation is completely 
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up to you. Your decision will not affect your ability to get health care or payment for your health 
care. It will not affect your enrollment in any health plan or benefits you can get. 
 
We may decide to have you stop being in the study even if you want to stay. Some reasons this 
could happen are if staying in the study may be bad for you, or if the study is stopped. 
 
Questions 
The investigator or a member of the research team will try to answer all of your questions. If 
you have questions or concerns at any time, contact Daniel Remick at 617-414-7914. 
 
You may also call 617-358-5372 or email medirb@bu.edu. You will be talking to someone 
at the Boston Medical Center and Boston University Medical Campus IRB. The IRB is a 
group that helps monitor research. You should call or email the IRB if you want to find out 
about your rights as a research subject. You should also call or email if you want to talk to 
someone who is not part of the study about your questions, concerns, or problems. 
 
By agreeing to be in this research, you are indicating that you have read this form (or it has 
been read to you), that your questions have been answered to your satisfaction, and that you 
voluntarily agree to participate in this research study. 
 
Subject:    
Printed name of subject 
 
By signing this consent form, you are indicating that 
• • you have read this form (or it has been read to you) 
• • your questions have been answered to your satisfaction 
• • you voluntarily agree to participate in this research study 
 
 
Signature of subject Date 
 
 
Researcher:    
Printed name of person conducting consent discussion 
 
I have personally explained the research to the above-named subject and answered all 
questions. I believe that the subject understands what is involved in the study and freely 
agrees to participate. 
 
 
  Signature of person conducting consent discussion                      Date 
 
To be completed by a witness if researcher reads this form to the subject 
This consent form was read to and apparently understood by the subject in my presence. 
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Printed name of witness (a person not otherwise associated with the study) 
 
 
Signature of witness                                                                             Date 
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